Taysha Gene Therapies, Inc.
A clinical-stage biotech developing gene therapies for rare nervous-system diseases. Founded in 2019 out of the University of Texas Southwestern Medical Center in Dallas, its lead program TSHA-102 is designed to treat the genetic root cause of Rett syndrome by delivering a single MECP2 gene directly into the spinal fluid. The company takes its name from the Caddo word "taysha," meaning "friend" or "ally" — the same word that gave Texas its name.
Bought 20.37M
Bought 42.5K · Sold 549.1K
Granted 3.09M · Bought 444.4K · Sold 178.1K
Granted 127.2K · Bought 777.8K
Granted 1.40M · Sold 224.0K
Granted 2.25M · Bought 15.0K · Sold 1.14M
Sold 63.0K
Granted 127.2K · Bought 114.1K
Granted 127.2K
Granted 127.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Manning Paul B10% owner · 12 transactions | — | 31.77Mas of Jun 2025 | — | 20.37M | — |
| Session R.A. II10% owner · 9 transactions | — | 9.15Mas of Jul 2023 | — | 42.5K | 549.1K |
| Nolan Sean P.Chief Executive Officer, Director · 6 transactions | +306.8% | 4.44M | 3.09M | 444.4K | 178.1K |
| Stalfort John A IIIDirector · 6 transactions | — | 2.06M | 127.2K | 777.8K | — |
| Alam KamranCHIEF FINANCIAL OFFICER · 15 transactions | +380.4% | 1.44M | 1.40M | — | 224.0K |
| Nagendran SukumarPresident and Head of R&D, Director · 20 transactions | +6851.1% | 1.34M | 2.25M | 15.0K | 1.14M |
| Prasad SuyashCMO and Head of R&D · 5 transactions | -10.6% | 530.6Kas of Jul 2022 | — | — | 63.0K |
| Donenberg Phillip B.Director · 5 transactions | — | 241.3K | 127.2K | 114.1K | — |
| Long Alison SDirector · 3 transactions | — | 127.2K | 127.2K | — | — |
| Sepp-Lorenzino LauraDirector · 3 transactions | — | 127.2K | 127.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +19.61M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.